Thomas Larouche

Physiologist, metabolism expert, passionate of pharmaceutical sciences, outdoor enthusiast and dad. My own views.

[Thomas Larouche @ThomasGrenier1]

@phillipwhite14 @NatRevCardiol @rob_mcgarrah Well done guys, congratulations!

[Thomas Larouche @ThomasGrenier1]

@ShoaClarke @ethanjweiss The bleeding rate is slightly higher in the polypill group. Maybe the difference is with aspirin compliance since a high proportion of patients were on dual antiplatelet
therapy?

[Alexandre Fisette @Physettes]

I am thrilled to announce the opening of the Fisette Lab, at the Université du Québec à Trois-Rivières, in Canada. It's an exciting new start and... I am actively looking for motivated recruits to study the neurobiology of nutrition! Please share! 1/3

[MICHAEL MILLER MD, MASPC @mmillermd1]

Superb editorial by my colleague @ScottWrightMD on #triglycerides & #CVD risk see Toth et al. https://t.co/iMsMRrGrsM @MayoClinic
@Amarincorp @nationallipid @ASPCardio @lipiddoc #EPA

[Juan Cosin Sales @JCosinSales]

J Armitatge y PG Steg en #ESCCongress discuten sobre los mecanismos del beneficio de omega-3 en #REDUCEIT ➡️ 1/3 lípidos + 1/3 efecto antitrombótico + 1/3 varios (⬇️PA, antiinflamatorio ...)

[Dr. Deepak L. Bhatt @DLBHATTMD]

Mitigating Risk Patients With Dyslipidemia https://t.co/nR7Kuqk3YX

[Medscape Education @MedscapeCME]

Highlights from #MedscapeLIVE "Reducing Residual Risk for #CVD: Omega-3 Fatty Acids in Cardiology Practice" at #ESCCongress:

6) Primary endpoint event rates were reduced from 89 to 61 per 1,000 patient-years

-w/ Dr. @DLBHATTMD of @BrighamWomens #cardiotwitter

[medRxiv @medrxivpreprint]

Apolipoprotein B underlies the causal relationship of circulating blood lipids with coronary heart disease https://t.co/oZLJ3GW74P #medRxiv

[Venk Murthy MD PhD @venkmurthy]

More data in @JACCJournals on the heterogeneity of HFPEF. Two groups with different prognosis:

* Older women with big LA non-CV death
* Younger men with LVH and CV/sudden death

#NotOneDisease

https://t.co/2VHcS98pqy

[Daniel J Drucker @DanielJDrucker]

@Novartis announces top line results from PARAGON-HF P3 RCT in #heartfailure with preserved ejection fraction (HFpEF) https://t.co/pfMdFYJ0kP

[Daniel J Drucker @DanielJDrucker]

@sanofi @sanofi drops sotagliflozin development #T2D #T1D #diabetes https://t.co/Lahnx3VsU3

[Diabetologia @DiabetologiaJnl]

#eGFR slope can be used in type 2 #diabetes as a surrogate endpoint for #renal outcomes, as well as to identify individuals at high risk of #cardiovascular disease and all-cause mortality @georgeinstitute #ESKD #CVD #T2DM 🔓 https://t.co/mELSqX69fT

[Jim Johnson, PhD @JimJohnsonSci]

AstraZeneca's Farxiga fails to get U.S. approval for Type-1 diabetes - Reuters https://t.co/yXQMi9fEtF

[Daniel J Drucker @DanielJDrucker]

EMPRISING the risk of HHF with commonly used second line therapy #Diabetes #Heartfailure @CircAHA https://t.co/iTux5QIlnW